BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Sep. 30, 2009
View Archived Issues
Plexxikon Drug Quickly Moves From Phase I to Pivotal Trials
In relatively short order, Plexxikon Inc. has moved its melanoma product from a Phase I study to pivotal trials, the first of which has begun enrolling patients. (BioWorld Today)
Read More
Dynavax: Phase III Heplisav Bid May Stretch to Europe, Canada
Read More
Repair Qualities of Macrophages, Hope for Muscle Regeneration
Read More
NewCo News: KemPharm: LATs Strengthen Safety of Available Therapies
Read More
'Dark' Days for Sequenom as Ax Falls on Top Executives
Read More
Other News To Note
Read More
Clinic Roundup
Read More
Financings Roundup
Read More